Lavinia Spain,Alexander Coulton,Irene Lobon,Andrew Rowan,Desiree Schnidrig,Scott T.C. Shepherd,Benjamin Shum,Fiona Byrne,Maria Goicoechea,Elisa Piperni,Lewis Au,Kim Edmonds,Eleanor Carlyle,Nikki Hunter,Alexandra Renn,Christina Messiou,Peta Hughes,Jaime Nobbs,Floris Foijer,Hilda van den Bos,Rene Wardenaar,Diana C.J. Spierings,Charlotte Spencer,Andreas M. Schmitt,Zayd Tippu,Karla Lingard,Lauren Grostate,Kema Peat,Kayleigh Kelly,Sarah Sarker,Sarah Vaughan,Mary Mangwende,Lauren Terry,Denise Kelly,Jennifer Biano,Aida Murra,Justine Korteweg,Charlotte Lewis,Molly O'Flaherty,Anne-Laure Cattin,Max Emmerich,Camille L. Gerard,Husayn Ahmed Pallikonda,Joanna Lynch,Robert Mason,Aljosja Rogiers,Hang Xu,Ariana Huebner,Nicholas McGranahan,Maise Al Bakir,Jun Murai,Cristina Naceur-Lombardelli,Elaine Borg,Miriam Mitchison,David A. Moore,Mary Falzon,Ian Proctor,Gordon W.H. Stamp,Emma L. Nye,Kate Young,Andrew J.S. Furness,Lisa Pickering,Ruby Stewart,Ula Mahadeva,Anna Green,James Larkin,Kevin Litchfield,Charles Swanton,Mariam Jamal-Hanjani,Samra Turajlic

Abstract:S. Table 1: List of PEACE Consortium members. S. Table 2: Sample database used for the study for Panel, Exome and RNASeq samples. S. Table 3: Overview of lines of treatment given to each patient. S. Table 4: Lesions and patients included in the lesion-level response to ICI analysis. S. Table 5: Hallmark genesets significantly upregulated in normal tissue vs tumor tissue. Table shows p-values for tissue type, purity; T value for tissue type, purity; q-value for tissue type, purity (FDR corrected). S. Table 6: Hallmark genesets significantly upregulated in tumor tissue vs normal tissue. Table shows p-values for tissue type, purity; T value for tissue type, purity; q-value for tissue type, purity (FDR corrected). S. Table 7: Genes included in the target panel. S. Table 8: Tree topology comparisons between manually constructed trees and pairtree-constructed trees.

Supplementary Tables from CD74–NRG1 Fusions in Lung Adenocarcinoma

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Tables 1-5 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Tables from A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer

Supplementary Tables S1-S19 from Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer

Supplemental Tables from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer

Supplementary Table S4 from Molecular Portraits of Epithelial, Mesenchymal, and Hybrid States in Lung Adenocarcinoma and Their Relevance to Survival

Supplementary Table S9 from the N6-methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma

Supplemental Table from TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: an Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table S6 from the N6-methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma

Supplementary Tables S1-S8 from Late-Stage Metastatic Melanoma Emerges Through a Diversity of Evolutionary Pathways

Supplementary Table 1 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Excel Tables from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators

Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Supplementary Tables 1 Through 8 from Immune Escape in Breast Cancer During in Situ to Invasive Carcinoma Transition

Supplementary Table S5 from an Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many Cancers

Supplementary Table 1 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes